Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | microtubule-associated protein tau | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | glucosidase, alpha | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | microtubule associated protein 2 | 0.0833 | 0.4201 | 1 |
Mycobacterium ulcerans | peptide deformylase | 0.1923 | 1 | 0.5 |
Onchocerca volvulus | 0.0114 | 0.0373 | 0.5 | |
Treponema pallidum | polypeptide deformylase (def) | 0.1923 | 1 | 0.5 |
Trypanosoma brucei | Peptide deformylase 2 | 0.0734 | 0.3672 | 1 |
Trichomonas vaginalis | alpha-glucosidase, putative | 0.0044 | 0 | 0.5 |
Loa Loa (eye worm) | glycosyl hydrolase family 31 protein | 0.0197 | 0.0814 | 1 |
Plasmodium vivax | peptide deformylase, putative | 0.1923 | 1 | 0.5 |
Trichomonas vaginalis | neutral alpha-glucosidase ab precursor, putative | 0.0044 | 0 | 0.5 |
Echinococcus multilocularis | lysosomal alpha glucosidase | 0.0197 | 0.0814 | 0.1939 |
Trichomonas vaginalis | sucrase-isomaltase, putative | 0.0044 | 0 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.0535 | 0.6566 |
Entamoeba histolytica | glycosyl hydrolase, family 31 protein | 0.0044 | 0 | 0.5 |
Trichomonas vaginalis | neutral alpha-glucosidase ab precursor, putative | 0.0044 | 0 | 0.5 |
Trichomonas vaginalis | alpha-glucosidase, putative | 0.0044 | 0 | 0.5 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.1923 | 1 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.1923 | 1 | 1 |
Leishmania major | polypeptide deformylase-like protein, putative | 0.0734 | 0.3672 | 1 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0833 | 0.4201 | 1 |
Wolbachia endosymbiont of Brugia malayi | peptide deformylase | 0.1923 | 1 | 0.5 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0833 | 0.4201 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.0535 | 0.6566 |
Echinococcus granulosus | lysosomal alpha glucosidase | 0.0197 | 0.0814 | 0.1939 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0734 | 0.3672 | 1 |
Trichomonas vaginalis | alpha-glucosidase, putative | 0.0044 | 0 | 0.5 |
Trypanosoma brucei | Polypeptide deformylase 1 | 0.0734 | 0.3672 | 1 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.0535 | 0.6566 |
Brugia malayi | Glycosyl hydrolases family 31 protein | 0.0197 | 0.0814 | 1 |
Mycobacterium tuberculosis | Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) | 0.1923 | 1 | 0.5 |
Trichomonas vaginalis | alpha-glucosidase, putative | 0.0044 | 0 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.1923 | 1 | 0.5 |
Schistosoma mansoni | alpha-glucosidase | 0.0169 | 0.0669 | 0.1592 |
Echinococcus multilocularis | lysosomal alpha glucosidase | 0.0197 | 0.0814 | 0.1939 |
Entamoeba histolytica | glycosyl hydrolase, family 31 protein | 0.0044 | 0 | 0.5 |
Trichomonas vaginalis | maltase-glucoamylase, putative | 0.0044 | 0 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0734 | 0.3672 | 1 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0734 | 0.3672 | 1 |
Schistosoma mansoni | alpha-glucosidase | 0.0169 | 0.0669 | 0.1592 |
Trichomonas vaginalis | alpha-glucosidase, putative | 0.0044 | 0 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0734 | 0.3672 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.5481 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 3.6964 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 7.9433 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen. (Class of assay: confirmatory) [Related pubchem assays: 1473, 1466 ] | ChEMBL. | No reference |
Potency (binding) | = 8.9125 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.